Different strategies have been pursued for continuing first-line EGFR-TKIs in patients with EGFR mutated NSCLC after the development of disease oligoprogression, such as continuation on EGFR-TKI alone or with chemotherapy, or with another targeted agent. This evidence concerns the gene EGFR and non-small cell lung carcinoma.